Alkem Laboratories has launched Pertuza, a biosimilar of pertuzumab, in India for treating HER2-positive breast cancer. This indigenously developed and manufactured injection of 420mg/14mL aims to provide an affordable treatment option. Alkem's CEO, Vikas Gupta, highlighted the launch as a commitment to strengthening their oncology portfolio and expanding access to crucial treatments.